Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Mortality and causes of death in a Swedish series of systemic sclerosis patients

Article Abstract:

Patients with systemic sclerosis (SSc) have a substantially higher rate of death than people in the general population, but oral cyclophosphamide does not appear to contribute to this excess mortality. SSc is an autoimmune connective tissue disease. Swedish researchers evaluated the progression of disease and mortality among 249 SSc patients over approximately 6 years. SSc patients had 4.6 times the risk of dying during the study period as the general population. Half of the deaths were from lung diseases such as pulmonary fibrosis, pulmonary hypertension, or lung cancer. Patients taking cyclophosphamide did not have a higher risk of fatal cancers.

Author: Scheja, Agneta, Akesson, Anita, Hesselstrand, Roger
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1998
Sweden, Patient outcomes, Mortality, Complications and side effects, Cyclophosphamide

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis

Article Abstract:

The extent of skin sclerosis and lung involvement may predict the clinical course of systemic sclerosis (SSc). SSc is a chronic connective tissue disease which can cause skin thickening, arthritis, muscle weakness, and organ dysfunction. Researchers in Spain studied 72 SSc patients to find relationships between symptoms and disease progression. Overall, 85% of patients were alive 10 years after symptoms began, but patients with skin disease confined below the elbows and knees, and those without significantly reduced lung function, had longer survival.

Author: Simeon, Carmen-Pilar, Armadans, Luis, Fonollosa, Vicent, Vilardell, Miquel, Candell, Jaume, Tolosa, Carles, Mearin, Fermin, Rodrigo, Maria Jose, Solans, Roser, Lima, Joan, Sampol, Gabriel
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1997
Prognosis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Decreased serum biochemical markers of muscle origin in patients with ankylosing spondylitis

Article Abstract:

The authors determined that patients with ankylosing spondylitis seem to have lower blood levels of various muscle-based biochemical markers than people without the disorder. This may be due to deterioration of certain proteins.

Author: Dijkmans, Ben A.C., Gooren, Louis J.G., Kostense, Piet J., Schaardenburg, Dirkjan van, Giltay, Erik J.
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1999
Measurement, Physiological aspects, Creatine kinase, Ankylosing spondylitis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Systemic scleroderma, Scleroderma (Disease)
Similar abstracts:
  • Abstracts: Mortality among U.S. veterans of the Persian Gulf war. A mechanism of central sleep apnea in patients with heart failure
  • Abstracts: The language of medical case histories. Systemic Amyloidosis Presenting with Angina Pectoris. Using systemic reviews in clinical education
  • Abstracts: Childhood activity and diet in prevention of obesity: a review of the evidence. Changing the nation's diet: a study of responses to current nutritional messages
  • Abstracts: Spontaneous eye blinking, a measure of dopaminergic function, in children with acquired immunodeficiency syndrome. part 2
  • Abstracts: Neonatology in residency curricula: how much is too much? Telephone-based interventions in outpatient care. Rheumatology outpatient training: time for a rethink?
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.